An NCI-designated Comprehensive Cancer Center
Srividya Swaminathan

Srividya Swaminathan, Ph.D.

Assistant Professor, Department of Systems Biology
Research Focus
  • Immune profiling of normal and malignant lymphopoiesis
  • Molecular mechanisms of immune modulation by oncogenes
  • Development of cell-based and non cell-based immunotherapies against lymphoid neoplasms
Dr. Swaminathan is a Scholar of the American Society of Hematology (ASH) and a Special Fellow of the Leukemia and Lymphoma Society (LLS) with ten years of research experience in Hematology-Oncology. She obtained her B Tech. degree from the Center for Biotechnology, Anna University, India, followed by a Ph.D. degree from the University of Southern California, Los Angeles. She carried out her doctoral studies in the laboratory of Dr. Markus Müschen, where she studied the cell-autonomous processes driving both normal B-lymphopoiesis, and precursor-B cell acute lymphoblastic leukemia (ALL). Subsequently, she trained as a postdoctoral scholar at the University of California, San Francisco (Mentor: Dr. Markus Müschen), and Stanford University (Mentor: Dr. Dean Felsher).
 
Prior to joining City of Hope, Dr. Swaminathan served as an Instructor in Dr. Felsher’s laboratory in the Department of Oncology, Stanford University, where she delineated the immunobiology of MYC oncogene-driven lymphomas. Dr. Swaminathan has authored a total of 8 peer-reviewed publications, with lead author research articles in Nature Medicine (2013), Nature Immunology (2015), and JITC (2018). The research focus of Dr. Swaminathan and her laboratory in the Department of Systems Biology will be identifying non-cytotoxic and targeted immunotherapies for treating oncogene-addicted B cell malignancies driven by MYC, MLL and ABL rearrangements; by comparing B cell-intrinsic processes, and the spatial and temporal distribution of the immune system during normal B-lymphopoiesis versus B cell lymphomagenesis. Her laboratory at the City of Hope is currently funded by a 5-year start-up package, the ASH Scholar Award and the LLS Special Fellow Award.
 

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Publications (peer-reviewed)
  • Duy C, Yu JJ, Nahar N, Swaminathan S, Kweon SM, Polo JM, Klemm L, Shojaee S, Cerchietti L, Hurtz C, Ramezani-Rad P, Jack HM, Herzog S, Jumaa H, Koeffler HP, Moreno de Alborán I, Melnick A, Ye BH, Müschen M. BCL6 is critical for the development of a diverse primary B cell repertoire. Journal of Experimental Medicine. 2010; 207. PMID: 20498019
  • Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011; 473. PMID: 21593872
  • Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Graeber T, Igarashi K, Carroll W, Willman C, Melnick A, Koeffler HP, Müschen M. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature Medicine. 2013; 19. PMID: 23852341
  • Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, MacMillan M, Müschen M, Kahn M, Kim YM. Small molecule inhibition of CBP/catenin interactions eliminates drug resistant clones in acute lymphoblastic leukemia. Oncogene. 2014; 33. PMID: 23728349
  • Masouleh BK, Geng H, Hurtz C, Chan LN, Logan AC, Chang M, Huang C, Swaminathan S, Sun H, Paeitta E, Melnick A, Koeffler HP, Müschen M. A mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences. 2014; 111. PMID: 24821775
  • Swaminathan S*, Klemm L*, Park E, Papaemmanuil E, Ford A, Kweon S-M, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan S, Casellas R, Schatz D, Lieber M, Greaves M, Müschen M. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nature Immunology. 2015; 16. PMID: 25985233. *Contributed equally.
  • Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann W-K, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell. 2015; 28. PMID: 26073130
  • Lai I*, Swaminathan S*, Baylot V, Mosley A, Dhanasekaran R, Gabay M, Felsher DW. Lipid Nanoparticles that Deliver IL-12 Messenger RNA can Suppress Tumorigenesis in MYC Oncogene-Driven Hepatocellular Carcinoma. Journal for Immunotherapy of Cancer. 2018. https://doi.org/10.1186/s40425-018-0431-x. *Contributed equally.
     
Publications (review articles)
  • Swaminathan S, Duy C, Müschen M. BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. Trends in Immunology. 2014; 35. PMID: 24332591
  • Swaminathan S, Müschen M. Follicular lymphoma: too many reminders for a memory B cell. Journal of Clinical Investigation. 2014; 124. PMID: 25384212
  • Buchner M, Swaminathan S, Chen Z, Müschen M. Mechanisms of pre-B cell receptor checkpoint control and its subversion in acute lymphoblastic leukemia. Immunological Reviews. 2014; 263. PMID: 25510278
  • Swaminathan S, Müschen M. Infectious origins of childhood leukemia. Oncotarget. 2015; 6. PMID: 26196452
In The News